Evaluate available evidence of physical and/or chemical compatibility of commonly used medications in critically ill patients with balanced crystalloids.
Data sources:
Ovid MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews were queried from inception to September 2022.
Study selection and data extraction:
This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. English-language studies reporting physical and/or chemical compatibility data between 50 selected medications and balanced crystalloids were included. A previously designed tool to assess risk of bias was adapted for use.
Data synthesis:
Twenty-nine studies encompassing 39 (78%) medications and 188 unique combinations with balanced crystalloids were included. Combinations included 35 (70%) medications with lactated Ringer’s, 26 (52%) medications with Plasma-Lyte, 10 (20%) medications with Normosol, and one (2%) medication with Isolyte. Studies commonly evaluated physical and chemical compatibility (55.2%). More medications were evaluated via Y-site than admixture. Incompatibilities were identified in 18% of combinations comprising 13 individual drugs.
Relevance to patient care and clinical practice:
This systematic review evaluates the compatibility of select critical care medications with balanced crystalloid solutions. Results may be used as a tool to guide clinicians on balanced crystalloid compatibility, potentially increasing ubiquitous use and reducing patient exposure to normal saline.
Conclusion and relevance:
Data are limited regarding chemical/physical compatibility of commonly used medications in critically ill patients with balanced crystalloids. Additional compatibility studies are warranted, particularly methodologically rigorous studies assessing Plasma-Lyte, Normosol, and Isolyte. Of the evaluated medications, there was a low frequency of incompatibilities with balanced crystalloids.
PernerAHaaseNGuttormsenAB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med. 2012;367(2):124-134. doi:10.1056/NEJMoa1204242
2.
FinferSBellomoRBoyceN, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247-2256. doi:10.1056/NEJMoa040232
3.
HammondNETaylorCFinferS, et al. Patterns of intravenous fluid resuscitation use in adult intensive care patients between 2007 and 2014: an international cross-sectional study. PLoS One. 2017;12(5):e0176292. doi:10.1371/journal.pone.0176292
4.
MyburghJCooperDJFinferS, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Engl J Med. 2007;357(9):874-884. doi:10.1056/NEJMoa067514
5.
YunosNMKimIBBellomoR, et al. The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med. 2011;39(11):2419-2424. doi:10.1097/CCM.0b013e31822571e5
6.
YunosNMBellomoRHegartyCStoryDHoLBaileyM.Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012;308(15):1566-1572. doi:10.1001/jama.2012.13356
7.
RaghunathanKShawANathansonB, et al. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med. 2014;42(7):1585-1591. doi:10.1097/CCM.0000000000000305
8.
YoungPBaileyMBeasleyR, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the SPLIT randomized clinical trial. JAMA. 2015;314(16):1701-1710. doi:10.1001/jama.2015.12334
9.
SemlerMWSelfWHRiceTW.Balanced crystalloids versus saline in critically ill adults. N Engl J Med. 2018;378(20):1949-1951. doi:10.1056/NEJMc1804294
10.
ZampieriFGMachadoFRBiondiRS, et al. Effect of intravenous fluid treatment with a balanced solution vs 0.9% saline solution on mortality in critically ill patients: the BaSICS randomized clinical trial. JAMA. 2021;326(9):1-12. doi:10.1001/jama.2021.11684
11.
FinferSMicallefSHammondN, et al. Balanced multielectrolyte solution versus saline in critically ill adults. N Engl J Med. 2022;386(9):815-826. doi:10.1056/NEJMoa2114464
12.
SemlerMWKellumJA.Balanced crystalloid solutions. Am J Respir Crit Care Med. 2019;199(8):952-960. doi:10.1164/rccm.201809-1677CI
13.
BrownRMWangLCostonTD, et al. Balanced crystalloids versus saline in sepsis. A secondary analysis of the SMART clinical trial. Am J Respir Crit Care Med. 2019;200(12):1487-1495. doi:10.1164/rccm.201903-0557OC
14.
HammondNEZampieriFGDi TannaGL, et al. Balanced crystalloids versus saline in critically ill adults: a systematic review with meta-analysis. NEJM Evid. 2022;1(2):1-12.
15.
MageeCABastinMLTLaineME, et al. Insidious harm of medication diluents as a contributor to cumulative volume and hyperchloremia: a prospective, open-label, sequential period pilot study. Crit Care Med. 2018;46(8):1217-1223. doi:10.1097/CCM.0000000000003191
16.
AcheampongAVincentJL.A positive fluid balance is an independent prognostic factor in patients with sepsis. Crit Care. 2015;19(1):251. doi:10.1186/s13054-015-0970-1
17.
PageMJMcKenzieJEBossuytPM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10(1):89. doi:10.1186/s13643-021-01626-4
KanjiSLamJJohansonC, et al. Systematic review of physical and chemical compatibility of commonly used medications administered by continuous infusion in intensive care units. Crit Care Med. 2010;38(9):1890-1898. doi:10.1097/CCM.0b013e3181e8adcc
PatelJAPhillipsGL.A guide to physical compatibility of intravenous drug admixtures. Am J Hosp Pharm. 1966;23:409-411.
22.
KirklandWDJonesRWEllisJR.Compatibility studies of parenteral admixtures. Am J Hosp Pharm. 1961;18:694-699.
23.
GrantHR.Compatibilities of intravenous admixtures. Hosp Pharmacist. 1962;15:67-70.
24.
DixonFWWeshalekJ.Physical compatibility of nine drugs in various intravenous solutions. Am J Hosp Pharm. 1972;29(10):822-823.
25.
GuptaDAgarwalARaoPBSrivastavaS.Physical incompatibility of phenytoin with Isolyte P. J Neurosurg Anesthesiol. 2007;19(4):288. doi:10.1097/ANA.0b013e318074c23b
26.
AkkermanSRZhangHMullinsREYaughnK. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 i.v. solutions. Am J Health Syst Pharm. 1999;56(1):63-68. doi:10.1093/ajhp/56.1.63
27.
WagenknechtDMBaaskeDMAlamASCarterJEShahJ.Stability of nitroglycerin solutions in polyolefin and glass containers. Am J Hosp Pharm. 1984;41(9):1807-1811.
28.
BaaskeDMDeMayJFLatonaCAMirmiraSSigvardsonKW.Stability of nicardipine hydrochloride in intravenous solutions. Am J Health Syst Pharm. 1996;53(14):1701-1705. doi:10.1093/ajhp/53.14.1701
29.
BaaskeDMDykstraSDWagenknechtDMKarnatzNN.Stability of esmolol hydrochloride in intravenous solutions. Am J Hosp Pharm. 1994;51(21):2693-2696.
30.
CloydJCBoschDESawchukRJ.Concentration-time profile of phenytoin after admixture with small volumes of intravenous fluids. Am J Hosp Pharm. 1978;35(1):45-48.
31.
KirschenbaumHLAronoffWPiltzGWPerentesisGPCutieAJ.Compatibility and stability of dobutamine hydrochloride with large-volume parenterals and selected additives. Am J Hosp Pharm. 1983;40(10):1690-1691.
32.
KirschenbaumHLAronoffWPerentesisGPPiltzGWGoldbergRJCutieAJ.Stability of dobutamine hydrochloride in selected large-volume parenterals. Am J Hosp Pharm. 1982;39(11):1923-1925.
33.
KirschenbaumHLAronoffWPerentesisGPPlitzGWCutieAJ.Stability and compatibility of lidocaine hydrochloride with selected large-volume parenterals and drug additives. Am J Hosp Pharm. 1982;39(6):1013-1015.
34.
CutieMRWaranisR.Compatibility of hydromorphone hydrochloride in large-volume parenterals. Am J Hosp Pharm. 1982;39(2):307-308.
35.
CutieMRLordiNG.Compatibility of verapamil hydrochloride injection in commonly used large-volume parenterals. Am J Hosp Pharm. 1980;37(5):675-676.
36.
DawsonRWignellACoolingPBarrettDVyasHDaviesP.Physico-chemical stability of Plasma-Lyte 148® and Plasma-Lyte 148® + 5% glucose with eight common intravenous medications. Paediatr Anaesth. 2019;29(2):186-192. doi:10.1111/pan.13554
37.
FisherDMCanfellCMillerRD.Stability of atracurium administered by infusion. Anesthesiology. 1984;61(3):347-348. doi:10.1097/00000542-198409000-00023
38.
GardellaLAZaroslinskiJFPossleyLH.Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 1: stability with common intravenous fluids. Am J Hosp Pharm. 1975;32(6):575-578.
39.
GayedAAKesharyPRHinkleRL.Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health Syst Pharm. 1995;52(5):516-520. doi:10.1093/ajhp/52.5.516
40.
HalpernNAColucciRDAliceaMGreensteinR.The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Clin Pharmacol Ther Toxicol. 1989;27(5):250-254.
41.
HammondSWignellACoolingPBarrettDADaviesP.Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Med Exp. 2020;8(1):25. doi:10.1186/s40635-020-00311-5
42.
MahonyCBrownJEStargelWWVergheseCPBjornssonTD.In vitro stability of sodium nitroprusside solutions for intravenous administration. J Pharm Sci. 1984;73(6):838-839. doi:10.1002/jps.2600730636
43.
SayreBEPrettymanTKaushalG.Extended stability of magnesium sulfate infusions prepared in polyolefin bags. Hosp Pharm. 2012;47(4):289-292.
44.
SzalaiGKatonaGMatuzMJójárt-LaczkovichODoróP.Physical compatibility of MCT/LCT propofol emulsions with crystalloids during simulated Y-site administration. Eur J Hosp Pharm. 2018;25(e2):e139-e143. doi:10.1136/ejhpharm-2017-001374
45.
TrisselLAPearsonSD.Storage of lorazepam in three injectable solutions in polyvinyl chloride and polyolefin bags. Am J Hosp Pharm. 1994;51(3):368-372.
46.
ValléeMBarthélémyIFriciuM, et al. Compatibility of lactated Ringer’s injection with 94 selected intravenous drugs during simulated Y-site administration. Hosp Pharm. 2021;56(4):228-234. doi:10.1177/0018578719888913
47.
YuenPHTaddeiCRWykaBEChaudryIA.Compatibility and stability of labetalol hydrochloride in commonly used intravenous solutions. Am J Hosp Pharm. 1983;40(6):1007-1009.
48.
HolykAALindnerAHLindnerSEShippertBW.Physical compatibility of Normosol-R with critical care medications used in patients with COVID-19 during simulated Y-site administration. Am J Health Syst Pharm. 2022;79(1):e27-e33. doi:10.1093/ajhp/zxab329
49.
WilderAGFousheeJAFoxLMNavalleJWrightAMGreerMA.Physical compatibility of medications used in critically ill patients with balanced fluid solutions. Int J Pharm Compd. 2020;24(3):238-241.
50.
Baxter Medical Information. Y-Site Compatibility of Intravenous Drugs with Plasmalyte 148. Deerfield, IL: Baxter Healthcare Corporation; 2017.
51.
SarverJGPrykaRAlexanderKSWeinsteinLErhardtPW.Stability of magnesium sulfate in 0.9% sodium chloride and lactated Ringer’s solutions. Int J Pharm Compd. 1998;2(5):385-388.
52.
HarperNJNPollardBJEdwardsDWilsonA. Stability of atracurium in dilute solutions. Int J Pharm. 1984;22:105-126.
53.
NeilJMFellAFSmithG.Evaluation of the stability of frusemide in intravenous infusions by reversed-phase high-performance liquid chromatography. Int J Pharm. 1984;22:105-126.
54.
PfeifleCEAdlerDSGannawayWL.Phenytoin sodium solubility in three intravenous solutions. Am J Hosp Pharm. 1981;38(3):358-362.
55.
DailyMed Database. Food and Drug Administration (FDA) Label Information. Bethesda, MD: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/index.cfm Accessed December 29, 2022.
56.
EllekjaerKLPernerAJensenMMMøllerMH.Lactate versus acetate buffered intravenous crystalloid solutions: a scoping review. Br J Anaesth. 2020;125(5):693-703. doi:10.1016/j.bja.2020.07.017
57.
BrownRMStollingsJLSemlerMW. Making the medicine go down: salt or sugar?Crit Care Med. 2018;46(8):1370-1371. doi:10.1097/CCM.0000000000003229
58.
BenlabedMPerezMGaudyR, et al. Clinical implications of intravenous drug incompatibilities in critically ill patients. Anaesth Crit Care Pain Med. 2019;38(2):173-180. doi:10.1016/j.accpm.2018.04.003
59.
BradleyJSWasselRTLeeLNambiarS.Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. Pediatrics. 2009;123(4):e609-e613. doi:10.1542/peds.2008-3080
60.
FeltonTWMcCormickBAFinferSRFisherMM.Life-threatening pulmonary hypertension and right ventricular failure complicating calcium and phosphate replacement in the intensive care unit. Anaesthesia. 2006;61(1):49-53. doi:10.1111/j.1365-2044.2005.04381.x
61.
HillSEHeldmanLSGooEDWhippoPEPerkinsonJC.Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr. 1996;20(1):81-87. doi:10.1177/014860719602000181
62.
LehrHABrunnerJRangoonwalaRKirkpatrickCJ.Particulate matter contamination of intravenous antibiotics aggravates loss of functional capillary density in postischemic striated muscle. Am J Respir Crit Care Med. 2002;165(4):514-520. doi:10.1164/ajrccm.165.4.2108033
63.
ReedyJSKuhlmanJEVoytovichM.Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high-resolution CT findings. Chest. 1999;115(3):892-895. doi:10.1378/chest.115.3.892
64.
TaniguchiTYamamotoKKobayashiT.Precipitate formed by thiopentone and vecuronium causes pulmonary embolism. Can J Anaesth. 1998;45(4):347-351. doi:10.1007/BF03012027
65.
FahimiFSefidani ForoughATaghikhaniSSaliminejadL.The rate of physicochemical incompatibilities, administration errors. Factors correlating with nurses’ errors. Iran J Pharm Res. 2015;14(Suppl):87-93.
66.
GikicMDi PaoloERPannatierACottingJ.Evaluation of physicochemical incompatibilities during parenteral drug administration in a paediatric intensive care unit. Pharm World Sci. 2000;22(3):88-91. doi:10.1023/a:1008780126781
67.
LeopoldinoRWCostaHTCostaTXMartinsRROliveiraAG.Potential drug incompatibilities in the neonatal intensive care unit: a network analysis approach. BMC Pharmacol Toxicol. 2018;19(1):83. doi:10.1186/s40360-018-0265-7
68.
TissotECornetteCDemolyPJacquetMBaraleFCapellierG.Medication errors at the administration stage in an intensive care unit. Intensive Care Med. 1999;25(4):353-359. doi:10.1007/s001340050857
69.
DevlinJWSkrobikYGelinasC, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
